TONEKABONI Seyed Hassan, EBRAHIMI Ahmad, BAKHSHANDEH BALI Mohammad Kazem, TAHERI OTAGHSARA Seyedeh Mohadeseh, HOUSHMAND Massoud, NASEHI Mohammad Mahdi, TAGHDIRI Mohammad Mahdi, MOGHADDASI Mehdi
Professor of Pediatric Neurology, Pediatric Neurology Research Center, Shahid Beheshi University of Medical Science, Tehran, Iran
PhD of Medical Molecular Genetic, Research Institute of Endocrine Sciences, Shahid Beheshi University of Medical Science, Tehran, Iran
Iran J Child Neurol. 2013 Spring;7(2):31-6.
Dravet syndrome or severe myoclonic epilepsy of infancy (SMEI) is a baleful epileptic encephalopathy that begins in the first year of life. This syndrome specified by febrile seizures followed by intractable epilepsy, disturbed psychomotor development, and ataxia. Clinical similarities between Dravet syndrome and generalized epilepsy with febrile seizure plus (GEFS+) includes occurrence of febrile seizures and joint molecular genetic etiology. Shared features of these two diseases support the idea that these two disorders represent a severity spectrum of the same illness. Nowadays, more than 60 heterozygous pattern SCN1A mutations, which many are de novo mutations, have been detected in Dravet syndrome.
MATERIALS & METHODS: From May 2008 to August 2012, 35 patients who referred to Pediatric Neurology Clinic of Mofid Children Hospital in Tehran were enrolled in this study. Entrance criterion of this study was having equal or more than four criteria for Dravet syndrome. We compared clinical features and genetic findings of the patients diagnosed as Dravet syndrome or GEFS+.
35 patients (15 girls and 20 boys) underwent genetic testing. Mean age of them was 7.7 years (a range of 13 months to 15 years). Three criteria that were best evident in SCN1A mutation positive patients are as follows: "Normal development before the onset of seizures, onset of seizure before age of one year, and psychomotor retardation after onset of seizures. Our genetic testing showed that 1 of 3 (33.3%) patients with clinical Dravet syndrome and 3 of 20 (15%) patients that diagnosed as GEFS+, had SCN1A mutation.
In this study, normal development before seizure onset, seizures beginning before age of one year and psychomotor retardation after age of two years are the most significant criteria in SCN1A mutation positive patients.
德雷维特综合征或婴儿严重肌阵挛性癫痫(SMEI)是一种始于生命第一年的严重癫痫性脑病。该综合征的特征为热性惊厥,随后出现难治性癫痫、精神运动发育障碍和共济失调。德雷维特综合征与伴有热性惊厥附加症的全身性癫痫(GEFS+)之间的临床相似性包括热性惊厥的发生以及共同的分子遗传学病因。这两种疾病的共同特征支持了这两种疾病代表同一种疾病严重程度谱的观点。如今,在德雷维特综合征中已检测到60多种杂合型SCN1A突变,其中许多是新发突变。
2008年5月至2012年8月,35名转诊至德黑兰莫菲德儿童医院儿科神经科门诊的患者纳入本研究。本研究的纳入标准是具有等于或超过四项德雷维特综合征标准。我们比较了诊断为德雷维特综合征或GEFS+的患者的临床特征和基因检测结果。
35例患者(15名女孩和20名男孩)接受了基因检测。他们的平均年龄为7.7岁(范围为13个月至15岁)。SCN1A突变阳性患者中最明显的三个标准如下:“癫痫发作前发育正常、一岁前癫痫发作、癫痫发作后精神运动发育迟缓”。我们的基因检测显示,3例临床诊断为德雷维特综合征的患者中有1例(33.3%)以及20例诊断为GEFS+的患者中有3例(15%)存在SCN1A突变。
在本研究中,癫痫发作前发育正常、一岁前开始癫痫发作以及两岁后精神运动发育迟缓是SCN1A突变阳性患者中最重要的标准。